Phage therapy is a promising strategy in the fight against MDR (Multi-Drug-Resistance) bacteria and may represent an additional therapeutic tool for their management. Researchers developed experience in liposomes loaded with selected bioactive lipids able to enhance bactericidal innate immunity and to limit inflammatory response (FFC#17/2013 and FFC#14/2017). The main goal of this project is the development of a novel combined therapeutic approach, based on bioactive liposomes and phages specific for Mycobacterium abscessus (Mab), being Mab used as a relevant example of MDR pathogen in Cystic Fibrosis (CF) patients. Mab bacteriophages will be encapsulated in selected liposome formulation. The new formulation will be experimented in mice chronically infected by Mab, as well as in macrophages infected with Mab, after being derived from CF and wild type mice, and from CF patients and healthy controls. This formulation is expected to be capable of enhancing the bactericidal innate immune response by both immunomodulatory and directly microbicide mechanisms, and simultaneously mitigating inflammation. It will possibly be an important new strategy for CF patients with recurrent Mab respiratory infections.